| Affiliation: | Baylor College of Medicine, Houston, Texas,; University College London, London, England,; The University of Texas M.D. Anderson Cancer Center, Houston, Texas,; Stanford University, Palo Alto, California,; Royal Marsden Hospital, London, England,; Baylor College of Medicine, Houston, Texas,; Northwest University, Chicago, Illinois,; Cooper University Hospital, Camden New Jersey,; Christie Hospital NHS Trust, Manchester, England, and; Aultman Cancer Center, Canton, Ohio |
| Abstract: | ![]()
This article summarizes the conclusions of a meeting of diverse breast cancer experts who discussed issues, controversies, and new clinical trial results relevant to the use of aromatase inhibitors for treating postmenopausal women with breast cancer. The new generation of aromatase inhibitors (anastrozole, letrozole, exemestane) have largely replaced megestrol acetate as a second-line therapy in postmenopausal women with hormone-responsive advanced breast cancer. In addition, anastrozole and letrozole have been shown to be superior to tamoxifen for first-line therapy. Finally, recent results suggest that anastrozole may be superior to tamoxifen as adjuvant therapy for early stage disease in postmenopausal women with hormone-responsive disease. |
